Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
In the grim lexicon of pancreatic cancer, one term casts a long, dark shadow: Pancreatic Ductal Adenocarcinoma (PDAC). It is the relentless juggernaut, the silent killer that dominates over 90% of diagnoses and dictates the narrative of despair. Lurking in…
The prognosis for pancreatic acinar cell carcinoma (ACC) has long been viewed through a grim, monolithic lens, often conflated with its notoriously aggressive cousin, pancreatic ductal adenocarcinoma (PDAC). Traditional statistics, citing a five-year survival rate hovering between 25-50% for resectable…
To ask for the “best” treatment for pancreatic acinar cell carcinoma (ACC) is to pose a question with a moving target. In the world of oncology, “best” is rarely a single, universally applicable protocol, but for a rare and enigmatic…
When we speak of pancreatic cancer, the mind often conjures a grim, well-defined portrait: painless jaundice, a silent killer discovered too late. This narrative, while tragically accurate for the more common pancreatic ductal adenocarcinoma (PDAC), dangerously obscures the unique and…
A cancer tissue microarray (TMA) is, at its core, an exercise in efficient pathology. But when it is infused with robust clinical annotations, it undergoes a profound metamorphosis. It ceases to be a mere collection of biological samples and evolves…
In the quiet archives of constant temperature and humidity in pathology departments all over the world, countless paraffin-embedded tissue blocks lie there quietly. They are not ordinary specimens, but biological “time capsules”, each of which solidifies a moment in the…
In the grand narrative of medical science, common diseases are like well-documented historical periods. We have rich cultural relics and extensive literature, and have a clear understanding of its social impact. Studying breast cancer or lung cancer is like studying…
In the vast and chaotic oncology universe, hepatocellular carcinoma (HCC) is as complicated as a nebula. It is not a single disease, but a galaxy composed of various heterogeneous malignant tumors, each of which has its own unique gene mutation,…
The conventional approach to validation treats the FFPE control block as a monolithic standard. An assay is developed, and its performance is evaluated against a seemingly stable reference material. Yet, this approach often fails to account for the myriad of pre-analytical factors that can profoundly…
For decades, the multi-organ tissue microarray (TMA) has served a crucial, albeit passive, role in pharmaceutical Research & Development: the safety net. In the preclinical stages, a novel compound is screened against a TMA containing heart, liver, kidney, lung, and…
